ALLUVI: A THOROUGH EXPLORATION INTO THE MEDICATION'S POSSIBILITY

Alluvi, previously known as LY3414901, represents a significant advancement in weight management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receiver agonist exhibits remarkable efficacy in early medical data, with impressive weight lo